BioMarin Pharmaceutical Quarterly Cash Flow Statement
NASDAQ: BMRNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 55.31 +0.94%
BioMarin Pharmaceutical free cash flow
In the quarter ended Jun 30, 2026, BioMarin Pharmaceutical generated $168.1 million of operating cash flow and spent $28.8 million on capital expenditures. That left free cash flow of $139.3 million, a free-cash-flow margin of 14.1% of revenue. Free cash flow was down 17.2% from the prior year's $168.2 million.
Summary generated from market data by MetaCap's automated system. Methodology
BioMarin Pharmaceutical cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 44.76M | 105.53M | -46.57M | -30.74M | 240.53M | 185.69M | 124.94M | 106.08M | 107.17M | 88.66M | 20.38M | 40.38M |
| Net Income growth (YoY) | -81.39% | -43.17% | -137.28% | -128.98% | +124.43% | +109.43% | +513.22% | +162.72% | +91.25% | +74.35% | — | — |
| Depreciation & Amortization | 97.64M | 16.41M | 20.44M | 18.49M | 18.56M | 22.07M | 23.61M | 19.01M | 26.46M | 27.35M | 26.86M | 25.68M |
| Stock-Based Compensation | 75.69M | 43.46M | 46.91M | 49.27M | 47.53M | 37.70M | 51.92M | 43.49M | 47.91M | 58.25M | 54.85M | 48.39M |
| Change in Working Capital | -49.87M | 49.13M | -199.17M | 155.13M | -137.43M | -82.51M | -57.45M | 69.58M | -75.14M | -75.90M | -95.83M | 61.07M |
| Operating Cash Flow | 168.11M | 220.65M | 99.64M | 368.69M | 185.27M | 174.39M | 185.63M | 221.48M | 118.76M | 46.97M | 27.48M | 135.65M |
| Capital Expenditures | -28.82M | -20.92M | -40.72M | -28.45M | -17.10M | -16.77M | -19.53M | -18.46M | -21.33M | -26.10M | -28.92M | -21.73M |
| Investing Cash Flow | -5.10B | 725.53M | -42.45M | -330.96M | -12.59M | -28.24M | 76.40M | -16.16M | 90.48M | -14.24M | -64.96M | -45.80M |
| Debt Issued | 2.80B | 850.00M | — | — | 0 | 0 | — | — | — | — | — | — |
| Financing Cash Flow | 2.74B | 813.17M | 3.16M | -2.17M | -4.60M | -38.78M | 2.86M | -499.13M | 12.61M | -42.79M | 10.84M | -788.00K |
| Net Change in Cash | -2.20B | 1.76B | 61.57M | 36.29M | 165.01M | 105.96M | 267.39M | -296.70M | 225.15M | -8.13M | -30.29M | 91.03M |
| Free Cash Flow | 139.29M | 199.73M | 58.92M | 340.24M | 168.17M | 157.63M | 166.10M | 203.02M | 97.44M | 20.87M | -1.43M | 113.91M |
This table shows 12 quarterly periods of BioMarin Pharmaceutical's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BMRN's reporting calendar. What is a cash flow statement?